The Role of MicroRNAs in Progressive Supranuclear Palsy-A Systematic Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Aug 10

PMID 39125813

Authors

Aleksandra Cwiklinska

Grzegorz Procyk

Dariusz Koziorowski

Stanislaw Szlufik

Affiliations

Soon will be listed here.

Abstract

Progressive supranuclear palsy (PSP) is a rare, neurodegenerative movement disorder. Together with multiple system atrophy (MSA), Dementia with Lewy bodies (DLB), and corticobasal degeneration (CBD), PSP forms a group of atypical parkinsonisms. The latest diagnostic criteria, published in 2017 by the Movement Disorders Society, classify PSP diagnosis into defined, probable, and possible categories based on clinical examination. However, no single test is specific and sensitive for this disease. Microribonucleic acids (miRNAs) are promising molecules, particularly in the case of diseases that lack appropriate diagnostic and treatment tools, which supports exploring their role in PSP. We aimed to systematically review the current knowledge about the role of miRNAs in PSP. This study was registered in the Open Science Framework Registry, and the protocol is available online. Primary original studies, both clinical and preclinical, written in English and assessing miRNAs in PSP were included. Systematic reviews, meta-analyses, reviews, case reports, letters to editors, commentaries, conference abstracts, guidelines/statements, expert opinions, preprints, and book chapters were excluded. The following five databases were searched: Embase, Medline Ultimate, PubMed, Scopus, and Web of Science. Each database was last searched on 18 June 2024. Eventually, nine original studies relevant to the discussed area were included. The risk of bias was not assessed. The selected research suggests that miRNAs may be considered promising biomarkers in PSP. However, the exact involvement of miRNAs in the pathogenesis of PSP is still to be determined. Several microRNAs were found to be dysregulated in patients with PSP. This applies to both brain tissue and fluids like cerebrospinal fluid CSF or blood. Several miRNAs were found that could potentially be helpful in differentiating among PSP patients, PD patients, and healthy individuals. Although some correlations and alterations have already been found, this field requires much more research. MicroRNAs are exciting and promising small molecules, and their investigation into many diseases, including PSP, may lead to significant discoveries.

References

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9. DOI: 10.1212/wnl.47.1.1. View

Nonaka W, Takata T, Iwama H, Komatsubara S, Kobara H, Kamada M . A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy. Mol Med Rep. 2022; 25(3). PMC: 8809115. DOI: 10.3892/mmr.2022.12604. View

Williams D, de Silva R, Paviour D, Pittman A, Watt H, Kilford L . Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain. 2005; 128(Pt 6):1247-58. DOI: 10.1093/brain/awh488. View

Lauretti E, Dincer O, Pratico D . Regional and temporal miRNAs expression profile in a transgenic mouse model of tauopathy: implication for its pathogenesis. Mol Psychiatry. 2020; 26(11):7020-7028. DOI: 10.1038/s41380-020-0655-2. View

Procyk G, Grodzka O, Procyk M, Gasecka A, Gluszek K, Wrzosek M . MicroRNAs in Myocarditis-Review of the Preclinical In Vivo Trials. Biomedicines. 2023; 11(10). PMC: 10604573. DOI: 10.3390/biomedicines11102723. View

Respondek G, Stamelou M, Kurz C, Ferguson L, Rajput A, Chiu W . The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014; 29(14):1758-66. DOI: 10.1002/mds.26054. View

Mahale R, Krishnan S, Divya K, Jisha V, Kishore A . Subtypes of PSP and Prognosis: A Retrospective Analysis. Ann Indian Acad Neurol. 2021; 24(1):56-62. PMC: 8061531. DOI: 10.4103/aian.AIAN_611_20. View

Ramaswamy P, Christopher R, Pal P, Debnath M, Yadav R . Plasma microRNAs as a Potential Biomarker for Identification of Progressive Supranuclear Palsy. Diagnostics (Basel). 2022; 12(5). PMC: 9139891. DOI: 10.3390/diagnostics12051204. View

Levin J, Kurz A, Arzberger T, Giese A, Hoglinger G . The Differential Diagnosis and Treatment of Atypical Parkinsonism. Dtsch Arztebl Int. 2016; 113(5):61-9. PMC: 4782269. DOI: 10.3238/arztebl.2016.0061. View

10.

Ha M, Kim V . Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509-24. DOI: 10.1038/nrm3838. View

11.

Tsuboi Y, Josephs K, Boeve B, Litvan I, Caselli R, Caviness J . Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord. 2005; 20(8):982-8. DOI: 10.1002/mds.20478. View

12.

de Gonzalo-Calvo D, Benitez I, Pinilla L, Carratala A, Moncusi-Moix A, Gort-Paniello C . Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. Transl Res. 2021; 236:147-159. PMC: 8149473. DOI: 10.1016/j.trsl.2021.05.004. View

13.

Barer Y, Chodick G, Cohen R, Grabarnik-John M, Ye X, Zamudio J . Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel. Brain Sci. 2022; 12(9). PMC: 9496895. DOI: 10.3390/brainsci12091126. View

14.

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

15.

Weber J, Baxter D, Zhang S, Huang D, Huang K, Lee M . The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11):1733-41. PMC: 4846276. DOI: 10.1373/clinchem.2010.147405. View

16.

Nelson P, Wang W, Rajeev B . MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 2008; 18(1):130-8. PMC: 2859437. DOI: 10.1111/j.1750-3639.2007.00120.x. View

17.

McFarland N . Diagnostic Approach to Atypical Parkinsonian Syndromes. Continuum (Minneap Minn). 2016; 22(4 Movement Disorders):1117-42. PMC: 5567217. DOI: 10.1212/CON.0000000000000348. View

18.

Park H, Ilango S, Litvan I . Environmental Risk Factors for Progressive Supranuclear Palsy. J Mov Disord. 2021; 14(2):103-113. PMC: 8175813. DOI: 10.14802/jmd.20173. View

19.

Zhu Q, Unmehopa U, Bossers K, Hu Y, Verwer R, Balesar R . MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer's disease. Brain. 2016; 139(Pt 3):908-21. DOI: 10.1093/brain/awv383. View

20.

Voglein J, Kostova I, Arzberger T, Roeber S, Schmitz P, Simons M . First symptom guides diagnosis and prognosis in neurodegenerative diseases-a retrospective study of autopsy proven cases. Eur J Neurol. 2021; 28(6):1801-1811. DOI: 10.1111/ene.14800. View